April 2026 in “Open MIND” GLP-1 medications can cause skin and muscle issues, but treatments like ultrasound and PRP can help.
59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
29 citations
,
September 2023 in “Journal of Clinical Medicine” Semaglutide helps obese PCOS patients lose weight and improve health.
25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” GLP1-RAs may have higher reports of suicidal events and hair loss compared to other diabetes drugs.
4 citations
,
March 2025 in “Journal of Cosmetic Dermatology” Semaglutide may cause hair loss, but more research is needed to confirm this.
1 citations
,
September 2025 in “Medicina Moderna - Modern Medicine” Combining lifestyle changes with personalized medication is crucial for better managing obesity in PCOS.
June 2026 in “Annals of Clinical Pathology” Methylene blue, combined with ceramides, may reduce skin and hair side effects from GLP-1 therapy.
June 2026 in “Dermatology and Therapy” GLP-1RAs, like semaglutide and tirzepatide, may cause hair loss, so patients should be informed and monitored.
May 2026 in “Pharmaceuticals” Incretin-based drugs for obesity often cause gastrointestinal issues, with tirzepatide having the most reports.
April 2026 in “Journal of Clinical Medicine” GLP-1 RAs may help wound healing but can also cause faster facial aging and skin issues.
April 2026 in “Science Progress” GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
A rash from semaglutide may be due to propylene glycol, not the drug itself.
October 2025 in “Brazilian Journal of Hair Health” Hair loss from weight-loss treatments is usually temporary and reversible.
February 2025 in “Skin Appendage Disorders” GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
September 2024 in “Journal of the American Academy of Dermatology” Semaglutide does not significantly increase the risk of hair loss.
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
2 citations
,
January 2025 in “Cutis” Glycemic control medications for Type 2 diabetes can affect skin conditions like psoriasis.
1 citations
,
September 2025 in “Dermatology and Therapy” GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.
February 2026 in “Editora Pasteur eBooks” A comprehensive, personalized approach is needed for treating female pattern hair loss and obesity, involving multiple medical disciplines and lifestyle changes.
January 2026 in “Quality in Sport” Semaglutide may help some skin disorders but can also cause skin issues.
May 2025 in “International Journal of Clinical Obstetrics and Gynaecology” A holistic approach, including lifestyle changes and surgery, is recommended for better long-term PCOS management.
Herbal supplements like Berberine, Cinnamon, and Fenugreek may be affordable alternatives for managing PCOS.
November 2024 in “Open Repository of the University of Porto (University of Porto)” Tailored medication preparation and ongoing education are crucial for effective treatments.
May 2024 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in patient education and personalized care.
Ayurvedic herbs may reduce side effects and improve effectiveness of cancer treatments.
August 2018 in “Journal of The American Academy of Dermatology” Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.
July 2024 in “Reactions Weekly”
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
July 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Pioglitazone combined with metformin or spironolactone improves PCOS symptoms and insulin resistance.